{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:27:45Z","timestamp":1789547265653,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jbspin.2012.08.005","type":"journal-article","created":{"date-parts":[[2012,9,27]],"date-time":"2012-09-27T21:37:22Z","timestamp":1348781842000},"page":"258-264","source":"Crossref","is-referenced-by-count":14,"title":["Bisphosphonates and glucocorticoid-induced osteoporosis: Efficacy and tolerability"],"prefix":"10.1016","volume":"80","author":[{"given":"Eric","family":"Lespessailles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2012.08.005_bib0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Utilisation of oral corticosteroids in the United Kingdom","volume":"93","author":"Van Staa","year":"2000","journal-title":"QJ Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0010","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/art.21194","article-title":"Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients","volume":"52","author":"Curtis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1136\/ard.2007.072157","article-title":"EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases","volume":"66","author":"Hoes","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0020","unstructured":"Recommandations de bonne pratique\u00a0: traitement m\u00e9dicamenteux de l\u2019ost\u00e9oporose cortisonique. ANSM (anciennement Agence Fran\u00e7aise de S\u00e9curit\u00e9 Sanitaire des Produits de Sant\u00e9). \u00c9dition 2003."},{"key":"10.1016\/j.jbspin.2012.08.005_bib0025","unstructured":"Guidelines working group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. Glucocorticoid-induced osteoporosis guidelines for prevention and treatment. London: Royal College of Physicians; 2002."},{"key":"10.1016\/j.jbspin.2012.08.005_bib0030","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard.2003.008060","article-title":"Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology","volume":"63","author":"Geusens","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0035","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/acr.20295","article-title":"American College of Rheumatology 2010: recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"62","author":"Grossman","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0040","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/art.30135","article-title":"Should bisphosphonates be used for long-term treatment of glucorcorticoid-induced osteoporosis?","volume":"63","author":"Teitelbaum","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0045","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0050","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-years effects of alendronate on bone mineral density and vertebral fractures in patients receiving glucocorticoids","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0055","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jc.83.4.1128","article-title":"Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss","volume":"83","author":"Roux","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","article-title":"Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis","volume":"337","author":"Adachi","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0065","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0070","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-induced osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteo (HORIZON): a multicentre, bouble-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0085","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0090","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis","volume":"11","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0100","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0105","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0110","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":"Use of Alendronate and risk of incident atrial fibrillation in women","volume":"168","author":"Heckbert","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0115","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","article-title":"Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population base case-control study","volume":"336","author":"Sorensen","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0120","first-page":"712","article-title":"Yearly zoledronic acid in post-menopausal osteoporosis","volume":"357","author":"Karam","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0125","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trial","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0130","unstructured":"http:\/\/www.fda.gov\/drug\/early_comm\/bisphosphonates_update_2008.htm."},{"key":"10.1016\/j.jbspin.2012.08.005_bib0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","article-title":"At rial fibrillation in fracture patients treated with oral bisphosphonates","volume":"265","author":"Abrahamsen","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0140","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00198-011-1608-z","article-title":"Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis","volume":"23","author":"Rhee","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0145","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0150","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0155","unstructured":"ANSM (past AFSSAPS). Recommandations on bucco-dental management of patients with bisphosphonates. 2007."},{"key":"10.1016\/j.jbspin.2012.08.005_bib0160","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2008.12.005","article-title":"Osteonecrosis of the jaw and the role of bisphosphonates: a critical review","volume":"122","author":"Silverman","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0170","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1359\/JBMR.051103","article-title":"Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice","volume":"21","author":"Lane","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0175","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/jbmr.160","article-title":"Glucocorticoid-induced autophagy in osteocytes","volume":"25","author":"Xia","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1601-6343.2009.01456.x","article-title":"Mandibular necrosis in beagle dogs treated with bisphosphonate","volume":"12","author":"Burr","year":"2009","journal-title":"Orthod Craniofac Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000151371","article-title":"Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench","volume":"189","author":"Allen","year":"2009","journal-title":"Cells Tissues Organs"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0190","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM198307073090105","article-title":"Association of adrenocorticosteroid therpy and peptic-ulcer disease","volume":"309","author":"Messer","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0195","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0205","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1124\/mol.59.2.193","article-title":"Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation","volume":"59","author":"Reszka","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Report of esophageal cancer with oral bisphosphonate use","volume":"360","author":"Wysowski","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0215","unstructured":"Cush JJ, Dao K. FDA reviews bisphosphonate safety. Drug Saf Q 2011;3:1."},{"key":"10.1016\/j.jbspin.2012.08.005_bib0220","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0225","doi-asserted-by":"crossref","first-page":"c4444","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"Green","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0230","first-page":"CD001347","article-title":"Bisphosphonates for steroid induced osteoporosis","author":"Homik","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0235","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0240","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0245","doi-asserted-by":"crossref","DOI":"10.2484\/rcr.v4i1.261","article-title":"Subtrochanteric femoral insufficiency fracture in women on bisphosphonate therapy for glucocorticoid-induced osteoporosis","volume":"4","author":"Bush","year":"2009","journal-title":"Radiol Case Rep"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0250","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0255","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1210\/jc.2010-1571","article-title":"Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis","volume":"95","author":"Abrahamsen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jbspin.2011.03.015","article-title":"What do we know about atypical femoral fracture? Insights and enigmas","volume":"78","author":"Audran","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0265","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society of Clinical and Economic Aspects of osteoporosis and osteoarthritis, and International Osteoporosis Foundation Working Group Report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0275","doi-asserted-by":"crossref","first-page":"12431","DOI":"10.1074\/jbc.274.18.12431","article-title":"GC induction of epithelial sodium channel expression in lung and renal epithelia occurs via trans-activation of a hormone response element in the 5\u2032-flanking region of the human epithelial sodium channel \u03b1 subunit gene","volume":"274","author":"Sayegh","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0280","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0285","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0290","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault Method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0295","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2005.03.006","article-title":"Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science","volume":"35","author":"Abadie","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0305","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0310","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00198-011-1804-x","article-title":"Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw","volume":"22","author":"Compston","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0320","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonate","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.362","article-title":"Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"26","author":"Hansen","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1138\/20110511","article-title":"New insights into the biology of glucocorticoid-induced osteoporosis","volume":"8","author":"Lane","year":"2011","journal-title":"IBMS Bone Key"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0335","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.2011.03994.x","article-title":"Clinical Question: what is the best approach to managing glucocorticoid-induced osteoporosis?","volume":"74","author":"Compston","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0340","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","article-title":"Advances in glucorticoid-induced osteoporosis","volume":"13","author":"Den Uyl","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2012.08.005_bib0345","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-012-1958-1","article-title":"A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis","author":"Lekamwasam","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X12001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T04:07:02Z","timestamp":1562213222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X12001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1297319X12001959"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2012.08.005","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}